ArticleFrontiers in endocrinology2026
DPA/AA ratio as a potential biomarker of primary aldosteronism in young and middle-aged adults.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary aldosteronism (PA) is a common cause of secondary hypertension, yet its diagnosis in young and middle-aged adults remains challenging due to low screening rates and complex testing procedures. Objective: This study aimed to investigate serum polyunsaturated fatty acid (PUFA) profiles, particularly the docosapentaenoic acid/arachidonic acid (DPA/AA) ratio, as novel biomarkers of PA in young adults. Methods: This 1:1 matched case-control study was performed on 138 young and middle-aged patients with PA and 138 essential hypertension (EH) controls. Serum PUFA levels were measured, and their associations with PA were analyzed using univariate and multivariate logistic regression analyses. Using bootstrap to conduct internal validation. The receiver operating characteristic (ROC) curve, calibration curve, and decision curve analysis (DCA) were employed to evaluate both the predictive performance and clinical practicability of the model. Results: Young and middle-aged patients with PA exhibited a distinct phenotype, including more severe hypertension, higher fasting blood glucose level, elevated low-density lipoprotein-cholesterol level, lower platelet count, and greater burden of left ventricular hypertrophy and albuminuria. A significantly reduced DPA/AA ratio was the most notable finding in the PA group. The multivariate analysis revealed DPA/AA as a strong independent inverse predictor of PA. Adding DPA/AA to a baseline model of traditional clinical and biochemical variables increased the area under the curve (AUC) from 0.849 to 0.866. The integration into a more comprehensive model also improved the AUC from 0.872 to 0.887. Conclusions: The DPA/AA ratio is a robust, independent biomarker of PA in young and middle-aged adults. Its incorporation into diagnostic models significantly enhances predictive accuracy, thus offering a promising noninvasive approach to improve early detection in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.